MICHAEL WISHER: Open Payments
NPI 1467454942 · HAUPPAUGE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,123 in 177 payments from 13 companies in 2025. Trend: 2023 $2,623 · 2024 $3,112 · 2025 $4,123
Food & beverage: $4,123
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $696 |
| Alkermes, Inc. | 22 | $693 |
| Neurocrine BioSciences, Inc. | 29 | $601 |
| Otsuka America Pharmaceutical, Inc. | 18 | $502 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $389 |
| Axsome Therapeutics, Inc. | 11 | $309 |
| Lundbeck LLC | 19 | $292 |
| E.R. Squibb & Sons, L.L.C. | 8 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $189 |
| Corium, LLC | 5 | $93 |
Products named: REXULTI, VRAYLAR, INGREZZA, ARISTADA, CAPLYTA, Auvelity, COBENFY, TRINTELLIX.
Industry payments across NY — which companies pay providers there.
